Article: Sankyo Signs as Subscriber to Nuclear Receptor Module of LifeSpan BioScience's DrugTarget Database; Agreement Is Sankyo's Second Subscription.

Business Editors/Health & Medical Writers

BIOWIRE2K

SEATTLE--(BW HealthWire)--July 23, 2002

LifeSpan BioSciences, Inc., a world leader in the emerging fields of molecular pathology and tissue proteomics, today announced that Sankyo Co., Ltd. of Tokyo, Japan has subscribed to the nuclear receptor (NR) module of LifeSpan's comprehensive DrugTarget Database. The NR module gives subscribers access to information on all major nuclear receptors for use in identifying and validating new gene targets for drug discovery. It is one of eight modules in LifeSpan's DrugTarget Database, which includes information on the gene families of greatest interest for ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!